Physician profile
Alan Chen
NPI 1619171576
$1,406.62
in general payments reported to CMS, 2019-2025
34 companies · $354 in 2025
The $354 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $260 · 2020: $53.70 · 2021: $112 · 2022: $191 · 2023: $168 · 2024: $267 · 2025: $354.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $790.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $789.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $142.95 | 2022-2024 | Senza |
| Depuy Synthes Sales INC. | $102.45 | 2019-2023 | Monovisc, Orthovisc |
| Smith+Nephew, INC. | $102.41 | 2020-2023 | Evos |
| Globus Medical, INC. | $95.89 | 2025 | Senza, Vyrsa V1 |
| Virtus Pharmaceuticals LLC | $84.22 | 2024 | Levorphanol Tartrate |
| Zimvie INC. | $71.69 | 2022 | |
| Horizon Therapeutics Plc | $57.42 | 2019 | |
| Boston Scientific Corporation | $54.43 | 2025 | Intracept |
| Merz Pharmaceuticals, LLC | $50.19 | 2023-2025 | Xeomin |
| Stryker Corporation | $49.81 | 2022 | |
| Zimmer Biomet Holdings, INC. | $49.32 | 2019-2021 | |
| Si-Bone, INC. | $48.85 | 2025 | |
| Djo, LLC | $46.90 | 2025 | Donjoy |
| Arteriocyte Medical Systems, INC. | $39.03 | 2019-2021 | |
| Vertex Pharmaceuticals Incorporated | $38.44 | 2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $33.52 | 2024 | Proclaim |
| Fidia Pharma USA INC. | $30.98 | 2019-2024 | Hyalgan, Hymovis, Triluron |
| Merck Sharp & Dohme LLC | $27.22 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $26.25 | 2023 | Iovera, Zilretta, Exparel |
| Axsome Therapeutics, INC. | $25.00 | 2025 | Symbravo |
| Ibsa Pharma INC. | $24.80 | 2024 | Licart, Flector, Tirosint |
| Azurity Pharmaceuticals, INC. | $21.95 | 2024 | Horizant |
| Innovation Technologies INC | $21.64 | 2024 | Irrisept |
| Heron Therapeutics, INC. | $18.27 | 2021 | |
| Ferring Pharmaceuticals INC. | $16.77 | 2020 | |
| Zyla Life Sciences, INC. | $16.68 | 2019 | |
| Avanos Medical | $16.67 | 2019 | |
| Medtronic, INC. | $16.41 | 2022 | |
| Collegium Pharmaceutical, INC. | $15.48 | 2025 | Xtampza |
| Kowa Pharmaceuticals America, INC. | $14.44 | 2022 | |
| Sanofi-Aventis U.S. LLC | $13.39 | 2019 | |
| Gilead Sciences, INC. | $12.91 | 2019 | |
| Endo Pharmaceuticals INC. | $11.68 | 2019 | |
| Merit Medical Systems INC | $8.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alan Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.